EPIDEMIOLOGY AND CLINICAL COURSE OF PATIENTS WITH CANCER DIAGNOSED WITH SARS-COV-2 INFECTION

I. Taladriz Sender, F.J. García Moreno, C. Villanueva Bueno, J. Vicente Valor, J.L. Revuelta Herrero, R. Collado Borrell, V. Escudero Villaplana, E. González-Haba Peña, Sanjurjo Sáez M
Servicio de Farmacia. Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (iISGM). Madrid, España

OBJECTIVES

Background: Cancer patients are supposed to be a vulnerable population for SARS-CoV-2 infection.

OBJECTIVE: to describe the epidemiology and clinical course of patients with cancer infected with SARS-CoV-2 who were attended in the hospital.

METHODS

• Design: Retrospective, observational study conducted in cancer patients who were attended in a tertiary hospital for SARS-CoV-2 infection during the period 03/01/2020-31/05/2020.
• Demographic and clinical variables were analyzed: comorbidities, tumor diagnosis, tumor stage and whether they had received anticancer treatment in the last month (active treatment).
• The clinical course was evaluated through:
  ✓ Hospital admission
  ✓ Pneumonia and oxygen therapy requirements
  ✓ Development of acute respiratory distress syndrome (ARDS)
  ✓ Admission to ICU and mortality rate.

RESULTS

112 patients
59.8% men
Mean age = 67±13.4 years
94.6% Caucasian, 4.4% latino

Comorbidities

▪ Smoking status: 61.6% non-smokers, 25% ex-smokers, 13.4% current smokers.
▪ Obesity = 11.6%
▪ Arterial hypertension = 57.1%
▪ Cardiovascular disease = 34.8%
▪ DM II = 32.1%
▪ COPD = 21.4%

Table 1. Cancer diagnosis and tumor stage

<table>
<thead>
<tr>
<th>The most frequent cancer diagnosis</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast cancer</td>
<td>21</td>
<td>18.8</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>20</td>
<td>17.9</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>18</td>
<td>16.1</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>14</td>
<td>12.5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tumor stage</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metastatic disease</td>
<td>62</td>
<td>55.4</td>
</tr>
<tr>
<td>Localized disease</td>
<td>28</td>
<td>25</td>
</tr>
<tr>
<td>Locally advanced disease</td>
<td>22</td>
<td>19.6</td>
</tr>
</tbody>
</table>

60.7% Patients had active cancer therapy

Graph 1. Cancer treatments

Chemotherapy 42%
Hormonal treatment 32%
Targeted therapy 7%
Immunotherapy 3%
Radiotherapy 7%

Upon admission:

✓ Pneumonia = 85.7% // Lymphopenia = 59.9% // pO2< 90% = 31.3%

Graph 2. Clinical Course

Mean days of admission = 16±17 days

CONCLUSIONS

• Mortality rate was high in all patients.
• Clinical course in patients with active anticancer treatment was very similar to that of the all cancer patients. Larger series of patients are needed to continue studying outcomes of SARS-CoV2 infection in cancer patients.